RP

Regeneron Pharmaceuticals

Every trial this sponsor leads in the registry, and everything it has published.

368All trials
Recruiting66
Recruited33
Not yet recruiting10
By invitation1
Completed199
Stopped55
Other4

110 active · 30% of this sponsor’s registry footprint

Oncology50 trials
Metabolic/Endocrine/Nutrition13 trials
Cardiovascular9 trials
Immunology & Inflammation7 trials
Dermatology4 trials
Haematology4 trials
Neurology3 trials
Renal & Urology3 trials

Not shown above: 2 Phase 1 healthy-volunteer trials and 7 trials whose condition matched no therapy area.

Trials by phase

Phase 1145
Phase 2105
Phase 390
Phase 412
Unphased16

Pipeline by phase · 45 drugs in active development

Phase 3 · 9 drugs

Cenvacibart (REGN7508)9 trials · 8 recruitingest. Feb 2027
Cemiplimab8 trials · 2 recruitingest. May 2027
Odronextamab7 trials · 4 recruitingest. Feb 2028
Fianlimab6 trials · 1 recruitingest. Mar 2027
Mibavademab3 trials · 3 recruitingest. Jun 2027
Garetosmab2 trialsest. Dec 2028

Phase 2 · 12 drugs

Fianlimab/Cemiplimab3 trials · 1 recruitingest. Nov 2026
Ubamatamab3 trials · 3 recruitingest. May 2027
ALN-ANG32 trials · 1 recruitingest. Dec 2026
ALN-CIDEB2 trials · 1 recruitingest. May 2027
ALN-PNP2 trials · 2 recruitingest. Aug 2027
Olatorepatide2 trials · 1 recruitingest. Nov 2026
Alirocumab1 trial · 1 recruitingest. Dec 2026
ALN-HSD1 trial · 1 recruitingest. Apr 2028

Phase 1 · 21 drugs

Vonsetamig2 trials · 1 recruitingest. Nov 2027
89Zr˗DFO˗REGN50541 trial · 1 recruitingest. Jan 2027
ALN-CFB1 trial · 1 recruitingest. Nov 2029
ALN-F12021 trial
ALN-SNCA1 trial · 1 recruitingest. Jun 2029
ALN-SOD1 trial · 1 recruitingest. Mar 2032
BPX-6011 trial · 1 recruitingest. Feb 2030
Davutamig (REGN5093)1 trial · 1 recruitingest. Apr 2032

Phase 4 · 3 drugs

Linvoseltamab12 trials · 10 recruitingest. Aug 2027
Dupilumab9 trials · 2 recruitingest. Oct 2026
Pozelimab5 trials · 5 recruitingest. Jul 2028

Active trials only, code names and brands merged. 199 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 5 of 10 curated

Multiple myeloma (Oncology)10 trials · 9 recruiting · 2 drugs1.3% of landscape
Obesity (Metabolic & Nutrition)4 trials · 3 recruiting · 4 drugs0.4% of landscape
Non-small cell lung cancer (Oncology)2 trials · 1 recruiting · 2 drugs0.1% of landscape
Atopic dermatitis (Dermatology)1 trial · 1 recruiting · 1 drug0.6% of landscape
Type 2 diabetes (Endocrinology)1 trial · 1 recruiting · 1 drug0.1% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon